Srinivas G Rao

This inventor holds 20 USPTO granted patents and 13 published patent applications, plus 3 CIPO patents and 6 EPO patents. Top assignees: Cypress Bioscience, Inc., Sova Pharmaceuticals, Inc., Atai Therapeutics Inc.. Active years: 2003-2024.

USPTO Granted Patents = 20 (Patent Applications = 13)

% Patents Active = 60.0

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 3.0

ph-index = 7

Forward Citations = 128(Granted Patents)

Location History:

San Diego, CA (US) (2003 - 2010)
Sunnyvale, CA (US) (2021 - 2023)
Encinitas, CA (US) (2010 - 2024)

Company Filing History:

7 out of 11

Cypress Bioscience, Inc.

patents

3 out of 3

Sova Pharmaceuticals, Inc.

patents

2 out of 17

Atai Therapeutics Inc.

patents

4. 2 out of 28

Collegium Pharmaceutical, Inc.

patents

5. 1 out of 2

Atai Life Sciences Ag

patents

6. 1 out of 44,831

Qualcomm Incorporated

patents

7. 4 out of 834,453

Other

patents

Years Active: 2003-2024

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12128027 - N—N-dimethyltryptamine (DMT) and DMT analog compositions, methods of making, and methods of use thereof (2024-10-29),

2. 12065405 - Prodrugs and conjugates of dimethyltryptamine (2024-08-20),

3. 11643391 - Prodrugs and conjugates of dimethyltryptamine (2023-05-09),

4. 11602521 - N,N-dimethyltryptamine compositions and methods (2023-03-14),

5. 11573195 - Solid state pH sensing continuous flow system (2023-02-07),

6. 11079350 - Solid state pH sensing continuous flow system (2021-08-03),

7. 10969360 - Solid state electrodes and sensors having redox active surface areas (2021-04-06),

8. 10227314 - Cystathionine-gamma-lyase (CSE) inhibitors (2019-03-12),

9. 9771339 - Cystathionine-γ-lyase (CSE) inhibitors (2017-09-26),

10. 9725426 - Cystathionine-γ-lyase (CSE) inhibitors (2017-08-08),

11. 8021687 - Modified release compositions of milnacipran (2011-09-20),

12. 7994220 - Milnacipran for the long-term treatment of fibromyalgia syndrome (2011-08-09),

13. 7915246 - Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain (2011-03-29),

14. 7888342 - Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain (2011-02-15),

15. 7820643 - Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain (2010-10-26),

Title: Innovations by Srinivas G Rao: A Leader in Pharmaceutical Patent Development

Introduction

Srinivas G Rao, based in Encinitas, CA, is a prolific inventor and researcher known for his substantial contributions to the field of pharmaceuticals. With a remarkable portfolio of 20 patents, Rao has made significant strides in the development of novel therapeutic compositions aimed at treating neurological disorders. His innovative approaches highlight the importance of scientific research in medicine and the development of effective treatments.

Latest Patents

Some of Rao's latest patents include ground-breaking work on N—N-dimethyltryptamine (DMT) and its analog compositions, focusing on the methods of making and using these compositions. One prominent patent details pharmaceutical formulations that include an amorphous N—N-dimethyltryptamine or a pharmaceutically acceptable salt or prodrug thereof, along with a polymeric carrier. These formulations are designed for buccal or sublingual administration, providing a novel approach to treat various medical conditions. Additionally, Rao has developed prodrugs and conjugates of dimethyltryptamine, encompassing compounds formulated for effective pharmacological use, highlighting the therapeutic potential of these innovative compounds.

Career Highlights

Rao’s career has seen fruitful associations with notable companies, most prominently Cypress Bioscience, Inc. His work in this organization, among others, has emphasized the importance of collaborative efforts in the advancement of pharmaceutical research and innovation. Rao's patents reflect his deep understanding and commitment to improving health outcomes through inventive solutions.

Collaborations

Throughout his career, Srinivas G Rao has collaborated with various esteemed professionals, including Jay D Kranzler and Sergio G Durón. These partnerships underscore the collaborative spirit necessary in pharmaceutical research, showcasing how teamwork elevates innovations to better serve patient needs.

Conclusion

Srinivas G Rao continues to be a pioneering force in the pharmaceutical industry. His extensive patent portfolio demonstrates his innovative spirit and dedication to developing effective treatments for neurological disorders. As research continues to evolve, Rao's contributions will undoubtedly play a crucial role in shaping future pharmaceutical advancements.